Skip to main content
HR 4053 118th Congress House Health Drug trafficking and controlled substances Government studies and investigations

Studying Suboxone Act

Introduced: June 13, 2023 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 16, 2023
Referred to the Subcommittee on Health.
Jun 13, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 13, 2023
Introduced in House
 Plain-English summary Congressional Research Service

Studying Suboxone Act 

This bill requires the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) to reevaluate the scheduling of buprenorphine-naloxone combination products (e.g., suboxone) under the Controlled Substances Act. These products are used to treat opioid addictions and are currently schedule III controlled substances. (A schedule III controlled substance is a drug, substance, or chemical that has less potential for abuse than a schedule I or II substance; that has a currently accepted medical use; and that has low or moderate risk of dependence if abused.)

Specifically, the bill requires HHS to review scientific and medical evaluations relating to these products and update its scheduling recommendations accordingly. The DEA must review the recommendations of HHS and make appropriate scheduling changes. 

What's happening now June 16, 2023

Referred to the Subcommittee on Health.

 Committees of jurisdiction 3
 Cosponsors 2
All 2 Democratic 1 Republican 1